Pancreatic Cancer Research

ResearcherNational Center for Global Health and MedicineActive in the last 2 years

Norihiro Kokudo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9003-8613; OpenAlex author ID A5008253796, A5028862176, A5108271032. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 11

  1. DNA hypermethylation of nonspecific cytotoxic cell receptor protein 1 and poor prognosis of pancreatic cancer. Co-author DOI 10.3892/ol.2026.15534↗
  2. A unique case of a typical pancreatic ductal adenocarcinoma that initially presented with a cystic component but underwent morphological changes. Last author DOI 10.1007/s12328-024-01958-3↗
  3. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  4. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  5. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Last author DOI 10.1016/j.bbrc.2017.12.083↗
  6. Predictors of Postoperative Non-Chylous Massive Discharge after Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1159/000479341↗
  7. Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer. Co-author DOI 10.1016/j.jcyt.2017.01.002↗
  8. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗
  9. Smad4 Decreases the Population of Pancreatic Cancer-Initiating Cells through Transcriptional Repression of ALDH1A1. Co-author DOI 10.1016/j.ajpath.2015.01.011↗
  10. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Co-author DOI 10.1093/carcin/bgu136↗
  11. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. Co-author DOI 10.1097/mpa.0000000000000139↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mai Nakamura · 2 shared papers, 2024–2026 · strength 0.53
  2. Kiyoshi Hasegawa · 5 shared papers, 2016–2018 · strength 0.36
  3. Yuki I. Kawamura · 1 shared paper, 2026 · strength 0.30
  4. Akio Saiura · 1 shared paper, 2026 · strength 0.30
  5. Taku Aoki · 5 shared papers, 2014–2018 · strength 0.29
  6. Yoshihiro Sakamoto · 4 shared papers, 2014–2018 · strength 0.24
  7. Yuka Nabeshima · 1 shared paper, 2024 · strength 0.23
  8. Mayumi Hoshikawa · 3 shared papers, 2016–2018 · strength 0.20
  9. Hiroyuki Isayama · 4 shared papers, 2014–2018 · strength 0.18
  10. Kazuhiko Koike · 4 shared papers, 2014–2018 · strength 0.18
  11. Yousuke Nakai · 4 shared papers, 2014–2018 · strength 0.18
  12. Kazuhiro Kakimi · 2 shared papers, 2017–2018 · strength 0.15
  13. Hideaki Ijichi · 3 shared papers, 2014–2018 · strength 0.14
  14. Michael B. Ghadimi · 1 shared paper, 2023 · strength 0.14
  15. Stefano Partelli · 1 shared paper, 2023 · strength 0.14
  16. Michael Bouvet · 1 shared paper, 2023 · strength 0.14
  17. Adnan A. Alseidi · 1 shared paper, 2023 · strength 0.14
  18. Lysanne D. A. N. de Muynck · 1 shared paper, 2023 · strength 0.14
  19. Thilo Hackert · 1 shared paper, 2023 · strength 0.14
  20. Takeaki Ishizawa · 1 shared paper, 2023 · strength 0.14
  21. Elena B. Rangelova · 1 shared paper, 2023 · strength 0.14
  22. J. Sven D. Mieog · 1 shared paper, 2023 · strength 0.14
  23. Massimo Falconi · 1 shared paper, 2023 · strength 0.14
  24. Chang Moo Kang · 1 shared paper, 2023 · strength 0.14
  25. Rutger‐Jan Swijnenburg · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.